# Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up

> **NCT03090503** · PHASE4 · UNKNOWN · sponsor: **Fundación Marques de Valdecilla** · enrollment: 200 (estimated)

## Conditions studied

- Schizophrenia
- Psychotic Disorders
- Psychosis

## Interventions

- **DRUG:** Aripiprazole
- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT03090503
- **Lead sponsor:** Fundación Marques de Valdecilla
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-06
- **Primary completion:** 2019-06
- **Final completion:** 2021-06
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2019-07-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03090503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03090503, "Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03090503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*